Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: MRA-PRRSV1

PROVIDER: PRJNA822997 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18596003_1.fastq.gz	Fastqsanger.gz
	SRR18596003_2.fastq.gz	Fastqsanger.gz
	SRR18596007_1.fastq.gz	Fastqsanger.gz
	SRR18596007_2.fastq.gz	Fastqsanger.gz
	SRR18596011_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 56

Similar Datasets

Evolution of gene expression levels in Anopheles male reproductive organs

Project description:Gene expression was determined for Male accessory gland and testes in different members of the Anopheles gambiae complex, including An. gambiae (Savannah, MRA-762), An. coluzzii (Mopti) [2], An. arabiensis [3], An. merus [4] and An. quadriannalatus [5. All the mosquito stocks were obtained from the Malaria Research and Reference Reagent Resource Center (MR4) in Atlanta (https://www.beiresources.org/Catalog/BEIVectors/MRA-762.aspx). References: 1. MR4 wild stocks information. Access Jenuary 2018. (Kisumu) https://www.beiresources.org/Catalog/BEIVectors/MRA-762.aspx 2. MR4 wild stocks information. Access Jenuary 2018. (Mopti) https://www.beiresources.org/Catalog/BEIVectors/MRA-763.aspx 3. MR4 wild stocks information. Access Jenuary 2018. (arabiensis) https://www.beiresources.org/Catalog/BEIVectors/MRA-856.aspx 4. MR4 wild stocks information. Access Jenuary 2018. (merus) https://www.beiresources.org/Catalog/BEIVectors/MRA-1156.aspx 5. MR4 wild stocks information. Access Jenuary 2018. (quadriannulatus) https://www.beiresources.org/Catalog/BEIVectors/MRA-1155.aspx

2018-12-31 | GSE117656 | GEO

Project description:MRA-Pantoea

| PRJNA1255394 | ENA

Non-steroidal mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy

Project description:The objective of this study was to test the novel non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone as a monotherapy in a preclinical Duchenne muscular dystrophy (DMD) model. Microarray was used to detail gene expression differences in ventricular heart tissue from finerenone-treated dystrophin-deficient, utrophin-haploinsufficient Het (utrn+/−; mdx) mice versus untreated Het mice.

2020-08-10 | GSE150302 | GEO

Aedes albopictus strain:MRA-804

Project description:Aedes albopictus strain:MRA-804 Transcriptome or Gene expression

| PRJNA327857 | ENA

Single cell transcriptomics and chromatin accessibility profiling elucidate the kidney protective mechanism of mineralocorticoid receptor antagonism [snATAC-seq]

Project description:Mineralocorticoids play a critical role in maintaining sodium and potassium homeostasis and pathophysiological processes including hypertrophy, inflammation and fibrosis. Mineralocorticoid antagonists (MRAs) have shown to protect from kidney and heart disease, however, their molecular mechanism of action is poorly understood. Here we performed single nuclei and bulk transcriptomics and chromatin accessibility analysis to characterize the mode of kidney protection by steroidal and non-steroidal MRA treatment in a rat model of mineralocorticoid-induced cardiorenal end-organ damage. We define mineralocorticoid sensitive cell types and gene network in the kidney. We show that in diseased kidneys specific proximal tubule cells develop an injured profibrotic phenotype expressing Spp1 and Il34. Nonsteroidal finerenone protects from profibrotic differentiation of proximal tubule cells. Profibrotic gene signature can classify human kidney tissue samples and predict prognosis. Our multi-omics approach elucidates target cell types and potential mechanisms of renal protection by finerenone.

2023-11-17 | GSE183840 | GEO

Project description:Identification of FLA and MRA from water of external anthropogenic and nosocomial environment

| PRJNA611042 | ENA

Single cell transcriptomics and chromatin accessibility profiling elucidate the kidney protective mechanism of mineralocorticoid receptor antagonism [bulk RNA-seq]

2023-11-17 | GSE183841 | GEO

Single cell transcriptomics and chromatin accessibility profiling elucidate the kidney protective mechanism of mineralocorticoid receptor antagonism [snRNA-seq]

2023-11-17 | GSE183839 | GEO

Homo sapiens

Project description:Human peripheral blood cells (PB): Effect of Tocilizumab/MRA compared to methotrexate(MTX) treatments on rheumatoid arthritis(RA) patients.

| PRJNA152397 | ENA

Gene Expression Analysis in Peripheral Blood of Patients with Rheumatoid Arthritis

Project description:Peripheral blood cells in patients with rheumatoid arthritis before/after IL-6 inhibition The obtained conclusions on the change of each gene expression level before and after MRA medication were as follows. (1) In the case of IL-6, the specific time profile that the expression level dropped at day 21 and increased to some extent at day 42 was observed in 2 of 18 subjects. In other subjects, quite small change or small increase after day 7 was observed. (2) In the case of IL-6R as well as in IL-6, the specific time profile that the expression level dropped at day 21 and increased to some extent at day 42 was observed in 1 of 18 subjects. In other subjects, slow and small increase was observed in 6 of 18. (3) The ratio of mRNA expression level of membrane and soluble type of IL-6R showed marginal difference after tocilizumab treatment, (4) The distinct change of expression level of cytochrome P450 mRNA after tocilizumab treatment was hardly observed in most patients.

2009-09-03 | GSE12653 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data